Soleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Purchased by Nuveen Asset Management LLC

Nuveen Asset Management LLC grew its stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 6.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 63,105 shares of the company's stock after acquiring an additional 3,627 shares during the quarter. Nuveen Asset Management LLC owned about 0.15% of Soleno Therapeutics worth $2,837,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Janus Henderson Group PLC lifted its holdings in shares of Soleno Therapeutics by 27.1% in the 4th quarter. Janus Henderson Group PLC now owns 5,188,265 shares of the company's stock valued at $233,130,000 after buying an additional 1,107,166 shares during the period. Nantahala Capital Management LLC increased its stake in Soleno Therapeutics by 20.1% during the 4th quarter. Nantahala Capital Management LLC now owns 3,928,966 shares of the company's stock worth $176,607,000 after buying an additional 658,518 shares in the last quarter. Avoro Capital Advisors LLC grew its position in shares of Soleno Therapeutics by 15.8% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,525,000 shares of the company's stock valued at $113,499,000 after purchasing an additional 344,000 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Soleno Therapeutics by 19.2% in the fourth quarter. Vanguard Group Inc. now owns 1,884,533 shares of the company's stock valued at $84,710,000 after purchasing an additional 303,806 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Soleno Therapeutics by 24.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,630,718 shares of the company's stock valued at $73,301,000 after purchasing an additional 321,223 shares in the last quarter. 97.42% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. HC Wainwright reiterated a "buy" rating and issued a $100.00 price objective on shares of Soleno Therapeutics in a research report on Tuesday, April 15th. Stifel Nicolaus raised their price target on Soleno Therapeutics from $74.00 to $108.00 and gave the company a "buy" rating in a research note on Friday, March 28th. Piper Sandler raised their price objective on Soleno Therapeutics from $93.00 to $145.00 and gave the stock an "overweight" rating in a report on Thursday, April 24th. Lifesci Capital raised Soleno Therapeutics to a "strong-buy" rating in a report on Tuesday, February 4th. Finally, Guggenheim raised their price target on Soleno Therapeutics from $81.00 to $97.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Soleno Therapeutics presently has a consensus rating of "Buy" and an average price target of $106.78.

Insider Buying and Selling at Soleno Therapeutics

In other news, CFO James H. Mackaness sold 90,622 shares of the company's stock in a transaction dated Thursday, March 27th. The shares were sold at an average price of $69.44, for a total value of $6,292,791.68. Following the sale, the chief financial officer now owns 105,176 shares in the company, valued at approximately $7,303,421.44. This represents a 46.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Bhatnagar Anish sold 699,095 shares of the company's stock in a transaction dated Thursday, March 27th. The shares were sold at an average price of $67.62, for a total transaction of $47,272,803.90. Following the completion of the sale, the chief executive officer now owns 577,076 shares in the company, valued at approximately $39,021,879.12. This trade represents a 54.78% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 942,672 shares of company stock worth $64,058,781. Insiders own 12.30% of the company's stock.

Soleno Therapeutics Price Performance

Shares of SLNO stock traded down $0.35 during midday trading on Wednesday, reaching $77.04. 435,595 shares of the company traded hands, compared to its average volume of 755,900. The firm's 50 day simple moving average is $72.24 and its two-hundred day simple moving average is $56.67. Soleno Therapeutics, Inc. has a 1-year low of $36.93 and a 1-year high of $80.99. The firm has a market cap of $3.88 billion, a PE ratio of -23.20 and a beta of -2.67.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.14) by $0.19. As a group, research analysts anticipate that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current fiscal year.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.